Skip to main content

In conversation with... RT Cure

How to detect arthritis earlier and prevent it.

A doctor discussing an arthritis diagnosis with a patient. Image by Vitaliy Abbasov via Shutterstock.
A doctor discussing an arthritis diagnosis with a patient. Image by Vitaliy Abbasov via Shutterstock.
 

About the RT Cure project

Although rheumatoid arthritis (RA) affects more than 18 million people worldwide, most people are diagnosed when the disease is already at a chronic stage. No drugs are currently approved to intervene in the early stages of arthritis, before the onset of joint inflammation. The RTCure project developed and validated new methods to identify those at risk of RA and monitor disease progression, as well as investigating how to inhibit or modify the pathogenic autoimmune responses underlying RA, an approach that could result in a specific and long-lasting therapeutic effect (ultimately a cure) for a majority of RA patients. The project also created tools to aid in the development of treatments for people in the earliest stages of rheumatoid arthritis and those at risk of developing it, and furthered understanding of the disease phase prior to RA diagnosis. RT Cure’s results indicated that the prevention of rheumatoid arthritis is possible – join us for In conversation with RT Cure to find out how.

About the event

This 45-min online event will discuss the RT Cure project, which was funded by the Innovative Medicines Initiative, a public-private partnership between the European Union and the European pharmaceuticals industry. The goal of this event is to showcase the project’s achievements to a wider, general audience discussing the value of the public-private partnership in boosting the uptake of the project’s results by industries, researchers, and clinicians, and demonstrating how the project has addressed key challenges in health research and innovation. The event will take the form of a panel discussion followed by a dedicated Q&A session moderated by IHI’s Scientific Officer, Manuel de la Guia Solaz. A recording will be available on the website shortly after the webinar.

Meet the speakers

alt
Lars Klareskog

Professor of Rheumatology

Department of Medicine

Karolinska Institutet

alt
Rowann Bowcutt

Director, Resolution of Inflammation

UCB Biopharma

alt

Professor of Rheumatology

Head of Centre for Rheumatic Diseases

Kings College London

alt
Manuel de la Guia Solaz

Scientific Officer

Innovative Health Initiative